Using DECT system, customized breast fixator and biphasic low‐dose data acquisition scheme, Park et al26 confirmed the significant correlation between quantitative CT perfusion data and immunohistochemical biomarkers, and significantly increased perfusion in high‐grade, ER‐negative or HER2‐positive cancers. This evidence concerns the gene ERBB2 and cancer.